Home LiteratureArticle Details
PMID: 1656853 Published · ppublish English Clinical Trial Controlled Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin.

Antimicrobial agents and chemotherapy ·Vol. 35 ·No. 6 ·1991-06-00 ·Pages 1081-4

Wise R, Logan M, Cooper M, Andrews JM

Abstract

The pharmacokinetics of tazobactam (500 mg) administered intravenously alone were compared with the pharmacokinetics of tazobactam coadministered with piperacillin (4 g), and the penetration into an inflammatory exudate in six healthy males was studied. Piperacillin influenced the pharmacokinetics of tazobactam. The mean levels of tazobactam in plasma at 4 h were 0.6 microgram/ml when it was given alone and 1.2 micrograms/ml when it was given with piperacillin (P = 0.0003). The mean total clearances of tazobactam were 203.5 and 134.2 ml/min (P = 0.035) when it was given alone and with piperacillin, respectively There were no significant differences in the elimination half lives, areas under the concentration-time curve from 0 h to infinity, or volumes of distribution. Inflammatory exudate penetration was rapid, and the mean maximum levels of tazobactam attained were 6.4 and 11.3 micrograms/ml when it was given alone or with piperacillin, respectively (P less than 0.06). The mean percent penetration of tazobactam and the area under the concentration-time curve from 0 h to infinity in inflammatory exudate were greater when tazobactam was given with piperacillin. The mean 24-h urinary recoveries of tazobactam were 63.7% +/- 7.9% when it was given alone and 56.8% +/- 2.7% when it was given with piperacillin. The explanation for the differences in the pharmacokinetics of tazobactam when it was administered alone compared with those when it was given with piperacillin was unclear.

MeSH Terms
Adult Biological Assay Blister/metabolism Drug Evaluation Drug Interactions Exudates and Transudates/metabolism Humans Inflammation/metabolism Injections, Intravenous Male Penicillanic Acid/administration & dosage,pharmacokinetics Piperacillin/administration & dosage,pharmacokinetics Tazobactam Tissue Distribution
Chemicals
Penicillanic Acid Tazobactam Piperacillin
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Wise R
Department of Medical Microbiology, Dudley Road Hospital, Birmingham, United Kingdom.
Logan M
Cooper M
Andrews J M
References (12)
12 references, click to expand
  1. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Antimicrob Agents Chemother. 1989 Nov;33(11):1964-9 PMID: 2558615
  2. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):495-510 PMID: 2560422
  3. Protection of piperacillin and ticarcillin from beta-lactamase hydrolysis by tazobactam (YTR-830) and clavulanic acid.
    J Antimicrob Chemother. 1989 Jul;24(1):89-92 PMID: 2550415
  4. In vitro activity of piperacillin, a new semisynthetic penicillin with an unusually broad spectrum of activity.
    Antimicrob Agents Chemother. 1978 Mar;13(3):349-57 PMID: 122518
  5. Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure.
    J Antimicrob Chemother. 1982 Feb;9 Suppl B:49-57 PMID: 6460734
  6. Simplified, accurate method for antibiotic assay of clinical specimens.
    Appl Microbiol. 1966 Mar;14(2):170-7 PMID: 4959982
  7. In vitro activity of ticarcillin plus clavulanic acid against bacteria isolated in three centers.
    Eur J Clin Microbiol. 1984 Jun;3(3):203-6 PMID: 6147246
  8. PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation.
    Comput Biol Med. 1984;14(1):25-34 PMID: 6546907
  9. In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin.
    J Antimicrob Chemother. 1980 Jul;6(4):455-70 PMID: 6968746
  10. CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.
    Antimicrob Agents Chemother. 1978 Sep;14(3):414-9 PMID: 309306
  11. The beta-lactamases of gram-negative bacteria and their possible physiological role.
    Adv Microb Physiol. 1973;9:31-88 PMID: 4581138
  12. The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.
    J Infect Dis. 1980 Jul;142(1):77-82 PMID: 7400630
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1991-06-00
Pages
1081-4
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC284290
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com